Introduction
Since the initial clinical report of Gardner and Dukes in 1955,1 non-specific vaginitis (NSV) has been recognised as a clinical entity. It has been described under different names and at present the condition is most commonly called bacterial vaginosis2 or vaginitis associated with gardnerella.3 It is probably related to the isolation of Gardnerella vaginalis, but other micro-organisms such as different anaerobic bacteria and so called comma shaped rods3 may be involved in the pathogenesis of the condition. There seems, however, to be a definite clinical condition, which is characterised by the following criteria: homogeneous, non-adherent vaginal discharge; pH of vaginal discharge >4 5-5 * 0; presence of clue cells in the discharge; amine-like smell after addition of 10% potassium hydroxide to the discharge. The clinical diagnosis of NSV requires that at least three of these criteria are present,2 and 0 vaginalis can be cultured from Table I shows the ages of our patients and duration of their symptoms before treatment. The ages were similar in all groups, but the duration of symptoms varied as some groups included patients with symptoms of very long duration. In all five groups of patients, after treatment there were significant (p<0 01) reductions in the frequency of malodour, the amount of vaginal discharge, and in the intensity of amine smell on addition of 10% potassium hydroxide (data not shown). Table IV shows the estimate of probability of the eradication of G vaginalis after treatment, as well as the 95%0 confidence interval estimate for that probability in each group. Again group D, in which patients were given 2000 mg metronidazole on days I and 3, showed the highest cure rate. Tables V and VI show the probability of the cure rate in each group, as estimated by the examining doctor and by the patient herself, and the estimate of the 95% confidence interval for each probability. Again Side effects were few and did not cause any of the patients to stop the treatment. A few patients complained of a metallic taste, but nausea was no problem in any of the groups. Table VII shows the isolation rates of C albicans before and after treatment. Patients in groups A and E, who were given the longest course of treatment, showed a significant (p<O 01) increase in isolations, which was not observed with shorter treatment regimens. In a 1 and 3 (group D) and 1200 mg daily for five days (group E), all showed satisfactory clinical results with high cure rates. In the group of patients given 1200 mg metronidazole daily for five days (group E) the reduction in the isolation of 0 vaginalis was significantly (p<O0I) lower than in the group given 2000 mg on days 1 and 3. Treatment for five or seven days was associated with significantly increased isolation of C albicans, probably due to the effect on the vaginal "ecosystem" of microflora. The clinical significance of increased C albicans isolation is uncertain, but it seems to indicate a shorter treatment time.
We conclude that treatment of NSV with metronidazole 2000 mg given in single doses on days 1 and 3 gives a high cure rate, has few side effects, and in most cases eradicates G vaginalis. This regimen can be recommended as a routine treatment for nonspecific vaginitis associated with gardnerella.
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